Patient in cardiogenic shock treated or not early with SGLT2 inhibitors. clinical trials

Effect of Early Empagliflozin Initiation in Cardiogenic Shock.

This study looks at whether adding a specific heart medicine, empagliflozin, early to standard care helps people with severe heart failure (cardiogenic shock). We want to see if it reduces deaths and hospital stays after 12 weeks compared to standard care alone.